

## Drug Utilization Review Board Minutes

February 24, 2016

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

### **Members Present:**

Lester Labus, MD, Chair  
K.C. Lovin, PA-C, Vice Chair  
C.K. Babcock, PharmD  
Christopher Booth, PharmD  
Scott Brown, RPh  
Myra Chiang, MD  
Karen Fitzpatrick, MD (via phone)  
Kate Forman, PharmD  
Michael Lonsinger, Pharm D  
Ernest Miller, DO  
Mary Nemeth-Pyles, MSN, RN, CS  
Pat Regan, PharmD  
Chris Terpening, PharmD, PhD  
John Vanin, MD

### **DHHR/BMS Staff Present**

Brian Thompson, MS, PharmD, DUR Coordinator  
Bill Hopkins, Pharmacy Operations Manager  
Doug Sorvig, Administrative Assistant

### **Contract Staff**

Steve Small, MS, RPh, Rational Drug Therapy Program (RDTP)  
Eric Sears, RPh, Molina Medicaid Solutions  
Brent Breeding, Goold Health Systems  
Matthew Waldrop, PharmD, Health Information Designs (HID)

## **I. INTRODUCTIONS**

- A. Dr. Lester Labus, Chairman, welcomed everyone to the Board meeting (4:00 p.m., EDT). The DUR Board and attendees introduced themselves. A motion was made, seconded, and approved to accept the minutes from the previous DUR Board meeting.

## II. OLD BUSINESS

- A. No old business to address.

## III. NEW BUSINESS

### A. **Speakers: 2 speakers**

- |                  |          |          |
|------------------|----------|----------|
| 1. Khoshal Bhatt | Novartis | Cosentyx |
| 2. James Hammond | Alkermes | Aristada |

### B. **Updates from the January 27, 2016 Pharmacy & Therapeutics Committee Meeting – Attachment A**

1. Dr. Labus and the Board reviewed the updates from the January 27<sup>th</sup> P&T meeting. No criteria changes were requested beyond those presented in section III-C of this document.

### C. **PDL Prior-Authorization Criteria – Attachment B**

1. **Namenda XR** – A motion to approve criteria as presented was made, seconded and passed.
2. **Cresemba** – A motion to approve criteria as presented was made, seconded and passed.
3. **Aristada** – A motion to approve criteria as presented was made, seconded and passed.
4. **Cosentyx** – A motion to approve criteria as presented was made, seconded and passed.
5. **Zepatier** – A motion to approve criteria as presented was made, seconded and passed.
6. **Hypoglycemics, Incretin mimetics/enhancers** – A motion to approve criteria as presented was made, seconded and passed.
7. **Hypoglycemics, Insulin and related agents** – A motion to approve criteria as presented was made, seconded and passed.
8. **Hypoglycemics, Meglitinides** – A motion to approve criteria as presented was made, seconded and passed.
9. **Hypoglycemics, TZD** – A motion to approve criteria as presented was made, seconded and passed.
10. **Irritable bowel syndrome/Short Bowel Syndrome/Selected GI Agents (Amitiza, Linzess, and Movantik)** – The Board was notified that WV Medicaid cannot require bulk laxatives in the PA criteria for these products. Medicaid presently only covers hyperosmotic laxatives. The current prior-authorization criteria were amended and a motion to accept was made, seconded and passed. An additional request was made by Dr. Babcock to investigate whether the covered services could be expanded to include other types of laxatives.

11. **Kynamro** – motion to approve criteria as presented was made, seconded and passed.
12. **Juxtapid** – motion to approve criteria as presented was made, seconded and passed.
13. **Repatha** – The Board requested changes to the presented criteria for the indication of ASCVD. A request was made to define the minimum LDL level required for prior-authorization of Repatha, and the PCSK9 inhibitors in general, when a diagnosis of ASCVD is present. A motion to hold for review at the next DUR Board meeting was made, seconded and passed.

#### IV. **REPORTS**

- A. **Molina Quarterly Report – Fourth Quarter 2015** – Eric Sears presented an overview of the Molina 2015 Fourth Quarter Report. The presentation included a review of the DUR Quarterly Overall Summary Report. (Attachment C)
- B. **Rational Drug Therapy Program** – Stephen Small presented a review of the prior authorization program for the Fourth Quarter 2015. The presentation included prior authorization approval rates, edit overrides, distribution, and therapeutic duplications. Other topics covered included the children’s stimulant, diabetes medication, sedative/hypnotic, and CDC BOOST grant programs. (Attachment D)
- C. **Health Information Designs** – Matthew Waldrop presented an overview of the Second and Fourth Quarter 2015 retrospective drug utilization activity. The presentation indicated the number of profiles reviewed, letters mailed to providers, rate of response, and evaluation of usefulness from the providers. The presentation also included an overview of activities in the Lock-In program and educational interventions completed. (Attachment E)

#### V. **OTHER BUSINESS – OPEN TO THE FLOOR**

- A. None

#### VI. **NEXT MEETING AND ADJOURNMENT**

- A. A motion to adjourn the meeting was made, seconded, and passed.
- B. The meeting concluded at 5:20 p.m., EDT.
- C. The next meeting will be Wednesday, May 25, 2016 from 4:00 p.m. – 6:00 p.m. and located at WVDHR.

Submitted:

Matthew Waldrop, PharmD, Health Information Designs.